Immatics N.V.
Immatics N.V. (IMTX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMTX · as of Jun 8, 2026
Key Statistics
Explore Immatics N.V. Data
imtx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 100.0%
The IMTX analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $25.00, representing +155.36% upside from the current price of $9.79.
Competitors & Peers
imtx competitorsIMTX
ATAI
CVAC
ELVN
INBX
NKTRStock Performance
Full HistoryAbout Immatics N.V.
Immatics N.V. a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The…
what is immatics n.v. · imtx stock overview · immatics n.v. company profile · who is immatics n.v. ceo · imtx NASDAQ · immatics n.v. headquarters · immatics n.v. business segments
About Stock Overview & Key Data
Immatics N.V. (IMTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 12, 2018. As of the latest trading session, IMTX stock price is $9.79, with a market capitalization of $1.3B. The stock has returned +62.58% over the past 12 months and -7.10% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Immatics N.V. stock is Buy, with an average 12-month price target of $25.00. In fiscal year 2025, Immatics N.V. reported revenue of $48.3M and net income of -$196.4M. For detailed data — including Immatics N.V. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Immatics N.V. (IMTX) stock price is $9.79. The stock is traded on NASDAQ under the ticker symbol IMTX. The 52-week range is $5.05 – $12.41.